Filing Flows

Filing Flows › Dianthus Therapeutics (DNTH) › Next earnings date

Dianthus Therapeutics (DNTH) earnings: beat the estimate

Dianthus Therapeutics (DNTH) reported on Nov 4, 2026 and beat the EPS estimate: −$0.81 against −$0.95 (+14.6%). It beat the EPS estimate in 60% of the quarters on record.

Last result+14.6% vs estimate
Beat rate60%

The last report

Dianthus Therapeutics reported revenue of $284K for the fourth quarter 2025 (-79% Y/Y), net loss $64.4M. How it makes money → · Every quarter →

Dianthus Therapeutics: EPS against the estimate, last 5 reportsDianthus Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.90−$0.97Nov 25−$1.03−$1.43Mar 26−$1.10−$0.85May 26−$0.91−$0.90Aug 26−$0.95−$0.81Nov 26
Latest (Nov 26): Estimate −$0.95, Reported −$0.81.

Dianthus Therapeutics' latest quarter

Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year), net loss $64.4M, operating cash flow −$47.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Dianthus Therapeutics beat earnings?

Dianthus Therapeutics (DNTH) reported on Nov 4, 2026 and beat the EPS estimate: −$0.81 against −$0.95 (+14.6%).

When does DNTH report earnings?

The next date is not set yet.

Does Dianthus Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.